TRANSFORMING HEALTHCARE WITH FIRST- AND BEST-IN-CLASS PEPTIDE THERAPEUTICS Research
Using our peptide technology platform, we have developed a pipeline of peptide and small molecule compounds that mimic or inhibit therapeutically relevant protein and protein interactions.
The platform has developed agonists and antagonists of various challenging targets such as cytokines, cytokine receptors, integrin, transmembrane solute transporters, GPCRs, and ion channels. With this technology, Protagonist Therapeutics engineers powerful drug candidates to potentially defeat blood cancers, ulcerative colitis, and other inflammatory diseases.
Treatments for Rare & Prevalent Diseases
We are creating new peptide-based treatments for blood disorders like polycythemia and inflammatory and immunomodulatory diseases like ulcerative colitis.
Groundbreaking Peptide Technology Platform
Through multiple tools, methods, and proprietary know-how, Protagonist engineers first and best-in-class peptide therapeutics to create desired degrees of potency, specificity, solubility, metabolic stability, and manufacturability.
Robust Late-Stage Development Pipeline
We are advancing a late stage peptide therapeutic candidate portfolio with significant market potential and a co-development partnership portfolio with Janssen Biotech.
Access to Our Innovation
We are committed to speeding the development of radically improved treatments for polycythemia vera (rusfertide), and inflammatory bowel disease (PN-493).